Psychiatry · AntipsychoticRegulatory Approvalcommercialmid-term

FDA Grants AP Status for Risperidone ANDA077494 Submission

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 12:31:58 AM

Assessment confidence: 69% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Risperidone indicates a significant shift in the competitive landscape. This could lead to increased market competition and pressure on pricing strategies for current branded products. Regulatory context from FDA (FDA AP — RISPERIDONE (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (12 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this generic entry on market share and pricing strategies for current Risperidone products. The strongest clinical anchor is A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenviron (ClinicalTrials.gov), mechanism alignment (io ). In Psychiatry · Antipsychotic, 8 regulatory and 3 competitive items passed relevance filtering for PH HEALTH.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for TZIELD (Teplizumab) Supplement (Humanexa Signals) — mechanism alignment (io ). Secondary pressure from FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement. This approval status may allow PH HEALTH to enter the market with a generic version of Risperidone, increasing competition against existing branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — RISPERIDONE (SUPPL) (FDA). Entity match (ph health); Regulatory pathway relevance (nda). While the approval status is a positive step for PH HEALTH, the final approval and market entry timeline will be critical for assessing compliance and regulatory implications.

Key Risks

Elevated medium regulatory exposure for PH HEALTH could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Status Epilepticus Population Study (STEPS)) could weigh on PH HEALTH through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of a generic version of Risperidone may erode market share and impact revenue for existing branded products, necessitating strategic adjustments.
Portfolio teams should assess the impact of this generic entry on market share and pricing strategies for current Risperidone products.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for final approval and market entry of the generic Risperidone by PH HEALTH.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — RISPERIDONE (SUPPL)
FDAhigh relevance
Entity match (ph health); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RISPERIDONE (SUPPL)
FDAhigh relevance
Entity match (risperidone); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RISPERIDONE (SUPPL)
FDAhigh relevance
Entity match (risperidone); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PERSERIS KIT (SUPPL)
FDAhigh relevance
Entity match (risperidone); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUPROLIDE ACETATE (SUPPL)
FDAhigh relevance
Entity match (ph health); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NDA219627
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Real-World Evidence Submissions to the Center for Drug Evaluation and Research
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Real-World Evidence Submissions to the Center for Biologics Evaluation and Research & the Center for Drug Evaluation and Research
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenviron
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
A Study of Remternetug (LY3372993) in Healthy Chinese Participants
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for TZIELD (Teplizumab) Supplement
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Significance of GSH and H(2)S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
' they just take one pill, so it is easy to use, more convenient ': South African health care provider perspectives on Dual Prevention Pill.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Potential implications of increased utilization of oral nirmatrelvir/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

PH HEALTH
Risperidone

Commercial impact

medium

The entry of a generic version of Risperidone may erode market share and impact revenue for existing branded products, necessitating strategic adjustments.

Regulatory impact

medium

While the approval status is a positive step for PH HEALTH, the final approval and market entry timeline will be critical for assessing compliance and regulatory implications.

What to watch

Monitor the timeline for final approval and market entry of the generic Risperidone by PH HEALTH.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.